-
Glucagon/GLP-1 receptor dual agonist demonstrates efficacy for obesity and MASLD
Matthias H. Tschöp, MD, and other researchers detailed phase 3 results of SYNCHRONIZE-1 and SYNCHRONIZE-MASLD showing that survodutide leads to significant weight loss, reduction in liver fat, and other health improvements.
-
REIMAGINE trials demonstrate efficacy of combination therapy for treating type 2 diabetes
Donna Ryan, MD, and other panelists reported on new data from phase 3 trials evaluating the combination of cagrilintide, which mimics amylin, and semaglutide, a glucagon-like peptide-1 receptor agonist, in adults.
-
Panel discussion addresses potential and challenges of stem cell-derived beta cell therapy for type 1 diabetes
Trevor Reichman, MD, moderated the discussion, which included insights into eligibility criteria, immunosuppression, regulatory concerns, and top priorities.
-
Speakers map the knowns, unknowns, and value of understanding diversity among people living with diabetes
Sherita Hill Golden, MD, MHS, and other presenters examined what needs to be done in diabetes care to better understand and provide treatment for the nation’s increasingly racially and ethnically diverse populations living with the disease.
-
Innovation Challenge elevates creative solutions to diabetes challenges
Leaders of three start-up ventures pitched their novel product ideas at the Scientific Sessions and exited with connections for opportunities to accelerate their visions for redefining diabetes care and treatment.
-
President of Medicine & Science calls for unifying biomedical science and social determinants of care
A. Enrique Caballero, MD, highlighted the progress advancing diabetes treatment and management while shedding light on existing gaps in care and advocating for integrating advances in science into the real-world context in which people live.
-
Triple-hormone therapy demonstrates efficacy for type 2 diabetes and obesity
Activation of the glucagon receptor with retatrutide is being investigated in a large phase 3 program that includes 14 trials and more than 22,000 participants. Researchers, including Ania Jastreboff, MD, PhD, shared data from two of the trials, TRANSCEND-T2D-1 and TRIUMPH-1.
-
Automated insulin delivery demonstrates efficacy in glycemic management in the hospital
Francisco Pasquel, MD, MPH, and other panelists presented new data from the AIDING trial, which compared automated inulin delivery to multiple daily injections combined with continuous glucose monitoring in individuals with type 1 diabetes or type 2 diabetes during hospitalization.
-
Experts to highlight innovative solutions for diabetes screening
Ines Casanova, PhD, and other presenters will explore strategies for closing diabetes screening gaps, including the findings from an ongoing initiative that deploys community health workers with mobile pop-up units into select areas.
-
Discussion to consider pragmatic solutions through diabetes technology across diverse demographics and settings
Michelle Litchman, PhD, APRN, FNP-BC, and other experts will examine data, challenges, and best practices around the use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) devices among children, older adults, the Deaf community, and inpatient populations.